Verrica Pharmaceuticals Inc (VRCA)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$3.53-7.83%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Verrica Pharmaceuticals Inc’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	7.31M
EPS	—	-0.477
Annual ending 2026-12-31
Revenue	—	24.39M
EPS	—	-2.045
Annual ending 2027-12-31
Revenue	—	39.22M
EPS	—	-1.338

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
EPS loss narrows from -$1.73 in FY26	A supporting condition in Verrica Pharmaceuticals Inc's published investment case. The stated target is EPS loss > -$1.73 but trending less negative.	Improving	EPS loss worsens beyond -$1.73 in FY26	Diluted EPS: $-0.62 per share FY2026-Q2; GAAP. Published target: EPS loss > -$1.73 but trending less negative. Target period is not explicitly aligned with this observation. Source published Aug 6, 2026-0.62 USD/share · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 0ec80ed3-475e-4351-8437-ca6c34ae77bf. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Operating income improves from -$9.7 million in Q1 2026	The company tries to improve its operating income from a loss of $9.7 million.	Broken	Operating loss worsens beyond -$9.7 million in Q1 2026	Operating income: $-13.097M FY2026-Q2; GAAP. Published target: Operating loss less negative than -$9.7 million. The stored target says 2026-Q1; this source reports FY2026-Q2. Fiscal/calendar alignment needs review. Source published Aug 6, 2026-13,097,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 0ec80ed3-475e-4351-8437-ca6c34ae77bf. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Revenue reaches at least $30 million in 2025	A primary condition in Verrica Pharmaceuticals Inc's published investment case. The stated target is >= $30.48 million.	Intact	Revenue falls below $30 million in FY25	Revenue: $5.862M FY2026-Q2; GAAP. Published target: >= $30.48 million. Target period is not explicitly aligned with this observation. Source published Aug 6, 20265,862,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 0ec80ed3-475e-4351-8437-ca6c34ae77bf. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS: comparable history unavailable.

FY2027 revenue$0.04B

Unavailable → $0.04B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	Unavailable	Unavailable	2 / 4
2026-07-25	Unavailable	Unavailable	2 / 4
2026-07-26	Unavailable	Unavailable	2 / 4
2026-07-27	Unavailable	Unavailable	2 / 4
2026-07-28	Unavailable	$46,258,800	3 / 5
2026-07-29	Unavailable	$46,258,800	3 / 5
2026-07-30	Unavailable	Unavailable	2 / 4
2026-07-31	Unavailable	Unavailable	2 / 4
2026-08-01	Unavailable	Unavailable	2 / 4
2026-08-02	Unavailable	Unavailable	2 / 4
2026-08-03	Unavailable	$46,258,800	3 / 5
2026-08-04	Unavailable	$46,258,800	3 / 5
2026-08-05	Unavailable	$46,258,800	3 / 5
2026-08-06	Unavailable	$46,258,800	3 / 5
2026-08-08	Unavailable	Unavailable	2 / 4
2026-08-09	Unavailable	$46,258,800	3 / 5
2026-08-10	Unavailable	Unavailable	2 / 4
2026-08-12	Unavailable	Unavailable	2 / 4
2026-08-13	Unavailable	Unavailable	2 / 4
2026-08-14	Unavailable	Unavailable	2 / 4
2026-08-15	Unavailable	Unavailable	2 / 4
2026-08-16	Unavailable	Unavailable	2 / 4
2026-08-17	Unavailable	Unavailable	2 / 4
2026-08-18	Unavailable	Unavailable	2 / 4
2026-08-19	Unavailable	Unavailable	2 / 4
2026-08-20	Unavailable	Unavailable	2 / 4
2026-08-21	Unavailable	Unavailable	2 / 4
2026-08-22	Unavailable	Unavailable	2 / 4
2026-08-23	Unavailable	Unavailable	2 / 4
2026-08-24	Unavailable	Unavailable	2 / 4
2026-08-25	Unavailable	Unavailable	2 / 4
2026-08-26	Unavailable	Unavailable	2 / 4
2026-08-27	Unavailable	Unavailable	2 / 4
2026-08-28	Unavailable	Unavailable	2 / 4
2026-08-29	Unavailable	Unavailable	2 / 4
2026-08-30	Unavailable	Unavailable	2 / 4
2026-08-31	Unavailable	$39,216,714	3 / 5
2026-09-01	Unavailable	$39,216,714	3 / 5
2026-09-02	Unavailable	$39,216,714	3 / 5
2026-09-03	Unavailable	$39,216,714	3 / 5
2026-09-04	Unavailable	$39,216,714	3 / 5
2026-09-05	Unavailable	$39,216,714	3 / 5
2026-09-06	Unavailable	$39,216,714	3 / 5
2026-09-07	Unavailable	$39,216,714	3 / 5
2026-09-08	Unavailable	$39,216,714	3 / 5
2026-09-09	Unavailable	$39,216,714	3 / 5
2026-09-10	Unavailable	$39,216,714	3 / 5
2026-09-11	Unavailable	$39,216,714	3 / 5
2026-09-12	Unavailable	$39,216,714	3 / 5
2026-09-13	Unavailable	$39,216,714	3 / 5
2026-09-14	Unavailable	$39,216,714	3 / 5
2026-09-15	Unavailable	$39,216,714	3 / 5
2026-09-16	Unavailable	$39,216,714	3 / 5
2026-09-17	Unavailable	$39,216,714	3 / 5
2026-09-18	Unavailable	$39,216,714	3 / 5
2026-09-19	Unavailable	$39,216,714	3 / 5
2026-09-20	Unavailable	$39,216,714	3 / 5
2026-09-21	Unavailable	$39,216,714	3 / 5
2026-09-22	Unavailable	$39,216,714	3 / 5
2026-09-23	Unavailable	$39,216,714	3 / 5
2026-09-24	Unavailable	$39,216,714	3 / 5
2026-09-25	Unavailable	$39,216,714	3 / 5
2026-09-26	Unavailable	$39,216,714	3 / 5
2026-09-27	Unavailable	$39,216,714	3 / 5
2026-09-28	Unavailable	$39,216,714	3 / 5
2026-09-29	Unavailable	$39,216,714	3 / 5
2026-09-30	Unavailable	$39,216,714	3 / 5
2026-10-01	Unavailable	$39,216,714	3 / 5
2026-10-02	Unavailable	$39,216,714	3 / 5
2026-10-03	Unavailable	$39,216,714	3 / 5
2026-10-04	Unavailable	$39,216,714	3 / 5
2026-10-05	Unavailable	$39,216,714	3 / 5
2026-10-06	Unavailable	$39,216,714	3 / 5
2026-10-07	Unavailable	$39,216,714	3 / 5
2026-10-08	Unavailable	$39,216,714	3 / 5
2026-10-09	Unavailable	$39,216,714	3 / 5
2026-10-10	Unavailable	$39,216,714	3 / 5
2026-10-11	Unavailable	$39,216,714	3 / 5
2026-10-12	Unavailable	$39,216,714	3 / 5
2026-10-13	Unavailable	$39,216,714	3 / 5
2026-10-14	Unavailable	$39,216,714	3 / 5
2026-10-15	Unavailable	$39,216,714	3 / 5
2026-10-16	Unavailable	$39,216,714	3 / 5
2026-10-17	Unavailable	$39,216,714	3 / 5
2026-10-18	Unavailable	$39,216,714	3 / 5
2026-10-19	Unavailable	$39,216,714	3 / 5
2026-10-20	Unavailable	$39,216,714	3 / 5
2026-10-21	Unavailable	$39,216,714	3 / 5
2026-10-22	Unavailable	$39,216,714	3 / 5
2026-10-23	Unavailable	$39,216,714	3 / 5
2026-10-24	Unavailable	$39,216,714	3 / 5

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	5	1
2026-06-01	5	1
2026-07-01	5	1
2026-08-01	5	1
2026-09-01	6	1
2026-10-01	6	1

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 6 Buy / Strong Buy · 1 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

EPS loss narrows from -$1.73 in FY26Diluted EPS: $-0.62 per share
Operating income improves from -$9.7 million in Q1 2026Published status: Broken
Revenue reaches at least $30 million in 2025Revenue: $5.862M

Next proof point

Nov 13, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.8%Typical daily move · historical

Downside history

-62.2%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Verrica Pharmaceuticals Inc outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a high-risk, loss-making commercial growth and clinical-development story, not an established compounder. Its multi-year view depends on continued YCANTH adoption and progress in common warts and basal cell carcinoma programs.

What's priced into Verrica Pharmaceuticals Inc

VRCA is described as cheap versus peers, while the pricing model has low confidence. The expectations gap is negative, suggesting expectations may be demanding relative to the evidence, though the snapshot gives no detail on which assumptions drive that gap.

What the fundamentals likely do

Near term, fundamentals remain weak: VRCA reported an earnings miss in August, and the next-quarter miss risk is elevated. On the positive side, Q2 YCANTH sales and dispensed units grew, and management is on track with its stated commercial priority; the broader business is still loss-making.

What Verrica Pharmaceuticals Inc hinges on

The multi-year thesis hinges on YCANTH sustaining commercial growth and on clinical progress, including the common warts trials with topline data expected in mid-2027. Near term, another guidance cut or weaker employment data could weigh on the outlook, while continued strength from major Healthcare companies could support the sector backdrop.